Index

A
Absolute concentration method, 128
Access, see under Health systems, AMR access
Accredited drug dispensing outlet (ADDO) project, 395–398
See also Health systems
Acinetobacter spp. resistance
bacterial resistant infections, 256–259
in Asia, 322
in Latin America and Caribbean, 441
Acquired drug resistance
TB and, 119–120
chronic case, 120
relapse, 120
return after default, 120
treatment failure aspects, 120
See also Intrinsic resistance
Acute otitis media (AOM), 494–495
Africa
antimicrobial resistance (AMR) in
African commensals, 270
containment, 451–452
in Northern Africa, 239–240, 469
MDR Salmonella, 304–305
MDR Shigella infections, 188–189
N. gonorrhoeae, 305
primary HIV, 88
surveillance, 468–469
VRE, 239–240
antimicrobial use in, 301
curative use by health professionals, 306
drug use improvement, 309–310
for cholera, 303–304
for malaria, 302
for XDR-TB, 306
poor-quality antimicrobials, 308–309
prophylactic use and expansion of indications for antimicrobials threatened by resistance, 305
unregulated use, 308
VRE in
North Africa, 239–240
South Africa, 240
See also Asia; Caribbean region; Latin America; Middle East; Tanzania health system (AMR access case study)
African trypanosomiasis
animal (AAT), 158, 161–164, 169–171
controlling chemotherapy for, 159–164
related challenges, 169–171
drug resistance in developing countries, 157–171
mechanisms, 166–168
human (HAT), 158–159
drug action mechanisms
diamidines, 165
difluoromethylornithine (DFMO), 165
dimazanese, 166
melarsoprol, 164–165
pentamidine, 165, 166
suramin, 165
SIT and, 160
Alliance for the Prudent Use of Antibiotics (APUA), 451–452, 457–458
Aminoglycoside
acetyltransferases (AAC), 22
nucleotidytransferases (ANT), 22
phosphotrases (APH), 22
resistance, 22
Aminoquinoline, 97
Amodiaquine, 97, 105, 112
Amoxicilllin, 209
Amphotericin B, 141
Ampicillins
for *Shigella* infections, 210
for *V. cholerae* infections, 212

Animal African trypanosomiases (AAT), 158, 161–164, 169–170
*See also* Human African trypanosomiases (AAT)

*Anopheles dirus*, 104
*Anopheles gambiae*, 111
*Anopheles stephensi*, 104

Antibiotic resistance, *see* Antimicrobial resistance (AMR)
Antibiotic use, *see* Antimicrobial use

Antifolates
as molecular marker of antimalarial resistance, 106–107
sulfadoxine, 97
*See also* Sulfadoxine–pyrimethamine (SP)

Antifungal drug resistance, 137–149
defined, 143–144
mechanisms, 139–143
azoles, 140–141
echinocandins, 142
flucytosine, 142
polyenes, 139
sulfamethoxazole, 142–143
*See also* Fungal infections

Anti-infective drugs, *see* Counterfeit drugs

Antimicrobial agents
classes, 404
impact on AMR development
fluoroquinolone, 408
MRSA, 408
penicillins, 407
tetracycline, 407
VRE, 408
interventions, 408–410
legislative framework and law enforcement, 410
pharmacy education, 409
public education, 409
surveillance and monitoring, 410
introduction in developing countries after antiretroviral therapy, 65–67
after quinolones therapy, 67–68
AMR development risk factors, 60–65
future aspects, 68
governmental and regulatory issues, 64–65
health-care institutional factors, 63–64
health-care provider factors, 62–63
impact on emergence of resistance, 59
patient-related factors, 63
resource-constrained settings, 60
social determinants risk factor, 61–62
mechanisms of action, 17–18
regulation, 404–405
types
bactericidal, 17
bacteriostatic, 17
unregulated sale and dispensing, 403
contributing factors, 405
interventions aspects, 408–410
prescription patterns and effect on AMR development, 406–407
*See also* Antimicrobial use

Antimicrobial resistance (AMR)
containment in developing countries, 355–357, 447
AMR detection and surveillance, 449–450
AMR morbidity and mortality aspects, 450–452
AMR root causes, 449
APUA role in, 457–458
capacity building of staff and infrastructure, 453
country national assessment on AMR, 454
ethical drug promotion, 505–521
Global Strategy for Containment of Antimicrobial Resistance, 448
health systems and containment, 385
in Africa, 451–452
in Asia, 452
in Latin American and the Caribbean, 453
interventions aspects, 408
leadership and advocacy role in, 457
lessons learned, 454–455
local research capabilities, 454
media role in, 457
policy and regulation role in, 457
providers’ education and training role in, 457
public awareness campaigns role in, 457
solution, 457–458
standard treatment guidelines (STGs), 456
substandard and counterfeit drugs, 454
vaccines for, 479–481
what has not worked?, 456
what has worked?, 455–456
drug resistance in developing countries
African trypanosomiasis, 157–171
antifungal drug resistance, 137–149
bacterial-resistant infections, 199–221
enteric pathogens, 177–192
enterococci, 233–241
gram-negative bacteria, 249–262
HIV, 75–90
M. tuberculosis (MTB), 117–133
malaria, 95–113
economic burden in developing
countries, 365
costs definition, 366–369
counterfeit of antimicrobial drugs, 379
diagnostics role (meningitis case study), 374–378
drug supply system intervention opportunities, 369–372
environmental cost of antimicrobial production and use, 379
malaria’s cost of resistance, 379–381
switching therapy economics, 372–374
wider and unintended consequences of antimicrobial use, 378
global perspectives, 3–12
biological, 4–5, 10
clinical, 11
compliance issues, 6
educational, 7
financial, 9–10
pharmacological, 6–7
regulatory, 8–9
wide-spectrum antibiotics, 6
hospital infections in developing countries, 345–355
in Africa, 299, 306–308
for cholera, 301–302
for malaria, 300
for multidrug-resistant Salmonella, 304–305
for N. gonorrhoeae, 305
for XDR-TB, 306
in Asia
bacterial infections, 315–323
fungi, 324
M. tuberculosis (TB), 323
in commensals, 269
African, 270
Asian, 271
Latin American, 272–273
Middle Eastern, 271
in enteric pathogens, 177–192
in Latin America and Caribbean, 331–342
mechanisms
acquired resistance, 19
aminoglycoside, 22
antimicrobial agents mechanisms of action, 17–18
antimicrobial use and resistance, 16–17
based on bacteria structure, 18
beta-lactam antibiotics, 19–20
chloramphenicol, 21
glycopeptide, 23–24
intrinsic or natural resistance, 19
macrolide, lincosamide, and streptogramin (MLS), 23
multidrug, 24–25
quinolone, 22–23
sulfonamides, 24
tetracycline, 20–21
trimethoprim, 24
media reporting
in India, 531–537
in Latin America, 525–531
poverty as root cause in developing countries, 27–33
See also Antimicrobial agents;
Antimicrobial use; Surveillance
Antimicrobial susceptibility testing (AST), 464–465
See also Surveillance
Antimicrobial use and resistance
in Africa, 301–310
in Asia, 315–324
in Latin America and Caribbean, 331–342
appropriate, 491–501
bacterial-resistant infections and, 218–220
by consumers, 295
antimicrobial folk culture popularity aspects, 287
antimicrobials as preventive agents, 288
powerful medicine aspects, 288
by dispensers, 295
by prescribers, 295–296
community interventions, 498–500
counterfeit drugs, 379
determinants, 293
economic, 293
lay networks, 285
of antimicrobial prescribing, dispensing and consumption, 287–294
Antimicrobial use (cont.)
pharmaceutical industry influence, 294
pharmacies, 285–286
physicians, 286
poorly understood and poorly researched, 283–297
self-medication aspects, 284–285
traditional medical practitioners, 286–287
dispensing and sales, 288–289
client demand, 289
knowledge of correct dispensing, 289
lack of regulation and enforcement, 289
environmental cost of antimicrobial production and use, 379
inappropriate, 492, 507–508
AMR biology and, 507–508
ethical considerations, 508–512
intervention studies, 494–495
medical students and residents, 495–498
prescription by qualified prescribers, 290–293
wider and unintended consequences, 378
Antiretrovirals
antimicrobial agents introduction after antiretroviral therapy, 65–67
for HIV, 76
HAART, 66, 76
resistance in developing countries, 75–90
adherence and emergence of HIV resistance, 79–80
NRTIs, 76, 79
primary HIV resistance measurement, 81–82
transmissibility of resistant viral strains, 82
treatment interruption and emergence of HIV resistance, 80–81
ZDV, 76
substandard, 421
therapy (ART), 76
emergence and transmission of resistant HIV and, 77, 79–82
implications and policy recommendations, 89–90
implications for HIV resistance, 82–84
primary HIV resistance measurement, 81–82
Artemisinin, 97
as molecular marker of antimalarial resistance, 108
combination therapies (ACTs), 100, 112, 377, 380, 512
derived drugs, 98
resistance, 99
See also Malaria
Asia
AMR containment in, 452
AMR surveillance networks
ANSORP, 468
DOMI, 468
SENTRY program, 467
antimicrobial use and resistance in
in Asian commensals, 271
bacterial infections, 315–323
fungi, 324
*Mycobacterium tuberculosis* (TB), 323
primary HIV resistance in, 86–88
VRE in
Central Asia, 234–236
East Asia, 233–234
See also Africa; Caribbean region; Latin America; Middle East
Asian Network for Surveillance of Resistant Pathogens (ANSORP), 468
*Aspergillus* spp., 138
Atovaquone, 97
as molecular marker of antimalarial resistance, 105
resistance, 99
Azidothymidine (AZT), see Zidovudine (ZDV)
Azithromycin
for *S. enterica* infections, 208
for *S. pneumoniae* infections, 205
Azoles
antifungal drug resistance mechanism, 140–141
resistance and
candidemia, 144–146
cryptococcosis, 146–147
invasive mold infections, 148
pneumocystis pneumonia (PCP), 147
See also Fungal infections
B
Bacterial infections, 199–200
antimicrobial use and resistance in Asia, 315–324
community-acquired infections, 315–318
nosocomial infections, 320–323
bacterial resistant infections, 199–221
Acinetobacter spp., 256–259
antibiotic use and, 218–220
C. jejuni, 213–215
Enterobacteriaceae, 253–256
N. gonorrhoeae, 215–217, 260
N. meningitidis, 261–262
P. aeruginosa, 256–259
S. aureus, 206–207
S. pneumoniae, 201–206
Salmonella spp., 207–209, 249–253
Shigella spp., 209–211, 252–253
surveillance aspects, 217–218
V. cholerae, 211–213
vaccines against, 480–481
See also Commensal bacteria; Enteric pathogens; Fungal infections; Gram-negative bacteria; Gram-positive bacteria
Bactericidal antimicrobial agents, 17
Bacteriostatic antimicrobial agents, 17
β-lactam antibiotics
in Latin America and Caribbean, 332–333
resistance mechanism, 19–20

C
Campylobacter spp.
bacterial-resistant infections, 213–215
multidrug-resistant
C. coli, 190
C. jejuni, 190
Candida infections
antifungal options for, 139
azoles for, 140
C. albicans-related, 140, 144–145
C. glabrata-related, 144–146
C. krusei-related, 145
C. parapsilosis-related, 144–145
candidemia, 144–146
candidiasis, 146
See also Fungal infections
Carbapenem resistance, 256, 340
Caribbean region
AMR containment in, 453
antimicrobial use and resistance in, 331
AMR surveillance, 332
gram-negative bacteria, 336–342
gram-positive bacteria, 332–336
VRE in, 236–239
See also Africa; Asia; Latin America; Middle East
Cefotaxime-hydrolysing Klebsiella spp., 181–182
Cephalosporin, 217
Cephalosporinases, 20
Chemotherapy, 159–164
Chloramphenicol
for C. jejuni infections, 215
for S. enterica infections, 207–209
for Shigella infections, 209–211
for V. cholerae infections, 211–213
resistance, 21
Chloroquine, 96, 112
antimalarial resistance mechanism, 104
as molecular marker of antimalarial resistance, 105–106
current status of drug-resistant malaria, 100
for malaria in Africa, 302–303
substandard, 420
See also Malaria
Chlorproguanil–dapsone (LapDap), 105
Cholera, 186–188
antimicrobial use and resistance in Africa for, 303–304
See also Vibrio cholerae
Ciprofloxacin
for C. jejuni infections, 215
for S. enterica infections, 207–208
for Shigella infections, 209
for V. cholerae infections, 211–212
Coagulase-negative staphylococci (CONS) infection, 349
Colorimetric methods, 129
Commensal bacteria
antibiotic resistance and, 267
as AMR reservoirs, 267–268
defined, 268–269
E. coli, 268–269
molecular approaches
DNA sequencing, 274–275
PCR methods, 275–276
PFGE, 275
surveillance through, 217–218
survey of resistance in
African commensals, 270
Asian commensals, 271
Latin American commensals, 272–273
Middle Eastern commensals, 271
See also Bacterial infections
Community-acquired infections
Community-acquired MRSA (CA-MRSA), 319, 335
diarrheal diseases and bacteremia
Community-acquired infections (cont.)
non-typhoid Salmonella species (NTS), 318
S. Typhi and Paratyphi, 317–318
in Asia, 315–320
in Latin America and Caribbean, 335
respiratory tract infections
H. influenzae, 316–317
M. catarrhalis, 317
macrolide-resistant S. pyogenes, 317
S. pneumoniae, 315, 316
sexually transmitted diseases (STD)
N. gonorrhoeae, 319
See also Nosocomial infections
Compliance based pharmacological issue, 6
Counterfeit drugs, 379
in developing countries, 413–436
consequences for individual patients, 431–432
counterfeit drugs and policy, 435–436
duty towards the community, 432–435
laboratory chemical analysis strategies, 423–429
prevalence of poor-quality anti-infectives, 415–423
rapid and inexpensive identification of poor-quality medicines, 429–431
See also Antimicrobial use
Cryptococcal infections
antifungal options for, 139, 141–142
azoles for, 140
cryptococcosis, 146–147
See also Fungal infections

D
Developing countries
AMR containment in, 447–458
AMR economic burden in, 365–382
antimicrobial agents
introduction in developing countries, 60–65
unregulated sale and dispensing, 403–410
antiretroviral drugs resistance in, 75–77
appropriate antibiotic use in, 491–501
ART delivery systems for HIV resistance, 78, 82–84
bacterial resistant infections in, 249–262
counterfeit drugs in, 413–436
drug resistance in
African trypanosomiasis, 157–171
antifungal, 137–149
bacterial-resistant infections, 199–221
enteric pathogens, 177–192
enterococci (VRE), 233–241
gram-negative bacteria, 249–262
HIV, 75–90
M. tuberculosis (MTB), 117–133
malaria, 95–113
empirical data on HIV primary resistance in
Africa, 87
Asia, 86–87
Latin America, 88
Russia and Eastern Europe, 88
ethical AMR drug promotion in, 505–521
future scope for resistance in, 37–49
alternatives to standard antimicrobial therapy, 49
challenges and possible solutions, 50–54
improvement of social and economic conditions, 48
infectious disease burden reduction aspects, 48
information flow improvement to consumers, 42–43
information flow improvement to health providers, 41–42
knowledge base improvement in care of individual patients, 39–40
knowledge base improvement in public health, 40–41
management capacity and systems, 46–47
regulation in private sector, 43–45
regulation in public sector, 45–46
HIV resistance, 87–88
hospital infections by AMR organisms in, 347–357
poverty as root cause of resistance, 27–33
See also Africa; Asia; Caribbean region; Latin America; Surveillance
Diamidines, 165
Diarrheal diseases and bacteremia, 317–318
Difluoromethylornithine (DFMO), 165, 170
Dihydrofolate reductase (DHFR), 24
Dihydropteroate synthase (DHPS), 24
Diminazene, 166, 171
Diphtheria vaccines, 480
Diseases of the Most Impoverished (DOMI), 468
dispensers, 295
distribution as pharmaceutical management activity, 387–388
microbial use and, 287–288
client demand, 289
knowledge of correct dispensing, 289
lack of regulation and enforcement, 289
unregulated sale and dispensing of antimicrobial agents, 403–410
See also Prescription; Health systems
DNA sequencing, 130, 274–275
MLST, 274
See also Commensal bacteria
Drug susceptibility testing (DST), see under Tuberculosis (TB)
Dysentery, 188–189, 209–210, 252
See also Shigella spp.

Echinocandin resistance, 139
antifungal drug resistance mechanism, 142
candidemia and, 145
Economic burden, see under Antimicrobial resistance (AMR)
Electrophoresis, 275
Enteric pathogens
AMR surveillance data for, 471–472
drug resistance in developing countries, 177–192
multidrug-resistant, 178
Campylobacter spp., 190
E. Coli, 178–181
Helicobacter species, 190–191
K. pneumoniae, 181–182
non-typhoidal Salmonella (NTS) infections, 182–185
S. enterica, 185–186
Shigella infections, 188–190
V. cholerae, 186–188
Salmonella enterica serotype
Paratyphi (S. Paratyphi), 207–209
Typhi (S. Typhi), 207–209
See also Bacterial infections;
Enterobacteriaceae infections;
Enterococcus spp.
Enterobacteriaceae infections
AMR surveillance data for, 470–471
bacterial resistant infections, 253–256
carbapenem and, 256
E. Coli, 253–254
ESBLs-producing, 253, 320–322
hospital infections by AMR organisms in developing countries, 347
Klebsiella spp., 253
nosocomial infections in Asia, 320–323
Enterococcus spp., 336
AMR in Latin America and Caribbean
E. aerogenes, 340
E. cloacae, 340
drug resistance in developing countries, 233–241
E. avium, 239
E. casselilflavus, 234
E. faecalis, 233–240
E. faecium, 233–240
E. gallinarum, 236, 240
See also Enteric pathogens; Vancomycin-resistant enterococci (VRE)
Erythromycin, 214–215
Escherichia Coli
AMR surveillance data for, 472–473
commensals, 267–277
Enterobacteriaceae infections and, 253–256
hospital infections by AMR organisms in developing countries, 347
multidrug-resistant E. coli from clinical and environmental sources, 178–181
Ethambutol, 125, 132
Ethical AMR drug promotion in developing countries
AMR biology and inappropriate drug use, 507
antimicrobial agents promotion and AMR emergence in pathogens, 516–518
antimicrobial use in food industry and adverse effects on human health, 514–516
building ethical frameworks based on resource availability, 508–510
‘control points’ mapping ‘drug representative’ as key mediator, 512–514
essential medicines library, 518–519
inappropriate drug use and, 507–508
moving beyond resource availability criteria in defining ethical thresholds, 510–512
Europe
primary HIV resistance in, 86
VRE in, 234–236
**Expanded Programme of Immunization (EPI),** 482, 487

*See also* Vaccines

**Extended-spectrum β-lactamase (ESBL)-producing bacteria**

AMR in Latin America and Caribbean, 338–340

Enterobacteraeae infections and, 253, 320–322

hospital infections by AMR organisms in developing countries, 347

nosocomial infections in Asia, 320–322

*Salmonella* infections, 252

**Extensively drug-resistant TB (XDR-TB),** 62, 119

definition, 115

epidemiology, 117

in Africa, 306

in Asia, 323

*See also* Multidrug-resistant TB (MDR-TB)

**F**

**Finance, health systems,** 390

**Fingerprinting analysis,** 428

**Fixed-dose combinations (FDCs),** 76

**Fluconazole resistance,** 141

candidemia and, 145–146

cryptococcosis and, 146

*See also* Fungal infections

**Flucytosine,** 139, 142

**Fluoroquinolone,** 67–68, 125

*AMR in Latin America and Caribbean,** 340

for *C. jejuni* infections, 214

for Enterobacteraeae infections, 253

for *N. meningitidis* infections, 262

for *S. enterica* infections, 208

for *S. Typhi* and *Paratyphi* infections, 207

for *Shigella* infections, 209

for *S. pneumoniae* infections, 206

for *V. cholerae* infections, 213

impact on AMR development, 408

**Food industry, antimicrobial use in,** 514–516

*See also* Ethical AMR drug promotion in developing countries

**Fungal infections**

antifungal drug resistance mechanism

*azoles,* 140–141

echinocandins, 142

*flucytosine,* 142

*polyenes,* 141

**G**

**Gambian sleeping sickness,** 158, 159

**Gastritis**

*Helicobacter* species and, 190–191

*See also* Enteric pathogens

**GenoType MTBDR,** 130

**Genotypic methods for TB testing,** 130

DNA sequencing, 129–130

real-time PCR, 131

solid-phase hybridization techniques, 130

**Global Fund for AIDS, Tuberculosis and Malaria (GFATM), The,** 380–381

**Global Salm-Surv project,** 249–250

**Global Strategy for Containment of Antimicrobial Resistance,** 448

**Glossina spp.,** 158

**Glycopeptide,** 233–234

resistance, 23–24

*See also* Vancomycin-resistant enterococci (VRE)

**Gonorrhoea,** *see Neisseria gonorrhoeae*

**Gram-negative bacteria**

*AMR in Latin America and Caribbean,* 336–342

**Acinetobacter,** 341

carbapenem resistance, 340

*E. aerogenes,* 340

*E. cloacae,* 340

**ESBL-producing bacteria,** 338–340

fluoroquinolone resistance, 340

*P. aeruginosa,* 341–342

drug resistance in developing countries, 249–262

**pathogens**

*A. baumannii,* 322

**ESBLs-producing Enterobacteraeae,** 320–321

*P. aeruginosa,* 321

**Index**
Gram-positive bacteria
AMR in Latin America and Caribbean, 332
CA-MRSA, 335
healthcare-associated MRSA, 334
MRSA, 334
nosocomial MRSA, 334
penicillin and β-lactam-resistant pneumococcus, 332–333
VISA, 335
VRE, 336
pathogens
MRSA and VISA, 322–323
VRE, 323

H
HAART (highly active antiretroviral treatment), 66, 76
Haemophilus influenzae
Hib vaccines, 481
respiratory tract infections, 315–317
Halofantrine, 97
Health systems
AMR access
measurement, 391–392
Tanzania case study, 394–398
AMR containment aspects, 385–392
finance, 388
human resources management, 388–389
information systems management, 389–390
medicines from health systems perspective, 386–392
pharmaceutical management
distribution activity, 388
procurement activity, 388
selection activity, 388
use activity, 388
stewardship and governance, 391–392
Helicobacter pylori, 190–191
Hepatitis B vaccines, 480–481
Hepatitis C virus (HCV), 479
HIV
antiretroviral drugs resistance aspects
NRTIs, 76, 82
primary resistance, 75
secondary resistance, 75
ZDVs, 76
defined, 75–76
drug resistance in developing countries, 75–90
antiretroviral therapy, 78–79
ART delivery systems, 82–84
implications and policy recommendations, 89–90
emergence and transmission of resistant HIV, 77
adherence and emergence of resistance, 79–80
mathematical models for, 84–86
primary HIV resistance measurement, 81–82
transmissibility of resistant viral strains, 82
treatment interruption and emergence of resistance, 80–81
fixed-dose combinations (FDCs) and, 76
NRTIs for, 76
primary resistance in developing countries
Africa, 87–88
Asia, 86–87
Latin America, 88
Russia and Eastern Europe, 88
zidovudine (ZDV) for, 76
Hospital infections
AMR and
containment strategies, 355–357
economic implications, 355
implications, 350–351
infection rates, 351–352
neonatal infections, 352–354
cogulase-negative staphylococci (CONS), 349
E. Coli, 349
Enterobacteriaceae, 349
K. pneumoniae, 349
MRSA, 348
MSSA, 348
Pseudomonas spp., 349
VRE, 349
Host, 103
See also Malaria
Human African trypanosomiasis (HAT), 158–159, 161–162, 164, 169–170
See also Animal African trypanosomiasis (AAT)
Human papilloma virus (HPV), 479
Human resources management, see under Health systems

I
In vitro tests, 108–109
India
India (cont.)
mass media analysis in, 531–533, 536–537
internet, 534
misuse or simplification of data for lay
audiences, 535
newspapers, 532–533
reporting problems and issues, 534–535
scientific reporting, 534
television, 533–534
trends and future directions, 537
See also Asia; Latin America
Infectious disease
vaccines against
bacterial infections, 480–481
viral infections, 479–480
See also Bacterial infections; Fungal
infections; Hospital infections
Information systems management, see under
Health systems
INNO-LiPA Rif TB assay, 130
Integrated Management of Childhood
Illnesses (IMCI), 32–33
Integrons, 24–25
Class 1, 25
Class 2, 25
Intermittent preventive treatment (IPT), 98
Internet
AMR mass media analysis
in India, 534
in Latin America, 526
See also Newspapers; Radio and
television
Intrinsic resistance, 19
See also Acquired resistance
Isometamidium, 171
Isoniazid, 132
Itraconazole, 141
K
Kanamycin, 125
Kinetoplastida, 157
Klebsiella pneumoniae
cefotaxime-hydrolysing and multidrug-
resistant, 181–182
Enterobacteriaceae infections and, 254
hospital infections by AMR organisms in
developing countries, 349
Korean Nationwide Surveillance of
Antimicrobial Resistance (KONSAR), 468
L
Latin America
AMR containment in, 453
antimicrobial use and resistance in, 331
AMR surveillance, 332
gram-negative bacteria, 336–342
gram-positive bacteria, 332–336
in commensals, 272–273
mass media analysis in
internet, 526
news reporting analysis, 527–530
newspapers, 527
radio and television, 525–526
recommendations and priorities for
improved news reporting, 530–531
primary HIV resistance in, 88
VRE in, 236–239
See also Africa; Asia; Middle East
Leishmania spp., 157–158
Lincosamide, see Macrolide, lincosamide,
and streptogramin (MLS)
Lomefloxacin, 210
Lumefantrine, 97, 112
M
Macrolide
for S. pneumoniae infections, 205
resistant S. pyogenes, 317
See also Pneumonia
Macrolide, lincosamide, and streptogramin
(MLS), 23
Malaria
ACT for, 380
antimalarial resistance mechanisms
drugs, 104–105
host, 103
parasite, vector and environment, 104
current status of drug-resistant
malaria, 100
drug resistance detection
in vitro tests, 108–109
in vivo tests, 109–110
drug resistance determinants
antimalarial drug resistance
definitions, 102–103
antimalarial resistance mechanisms,
103–106
treatment failure factors, 101–102
drug resistance in developing countries,
95–113
artemisinin, 99
atovaquone, 99
chloroquine, 98
cost payment aspects, 379–381
current status of drug-resistant malaria, 100
future prospects, 111–112
in Africa, 302–303
mefloquine, 99
piperaquine, 99
primaquine, 99
quinine, 97, 98–99
SP, 98
molecular markers of antimalarial resistance, 105, 110
antifolates, 106–107
artemisinin, 108
atovaquone, 107–108
chloroquine, 106
mefloquine, 107
quinine, 107
sulfadoxine–pyrimethamine (SP) for, 96, 106–107
treatment and emergence of resistance, 97–99
Mathematical models
for HIV resistance study
emergence and evolution of resistance within individuals, 85
operational questions, 84
transmission of drug resistance, 85–86

See also Antiretrovirals
Measles vaccine, 479–480
Media reporting, AMR
analysis, 527–530
in India, 531–537
in Latin America, 525–531
Mefloquine, 97, 99
antimalarial resistance mechanism, 105
as molecular marker of antimalarial resistance, 107–108
Melarsoprol, 164–165, 170
Meningitis
diagnostics role case study (AMR economics), 374–378

See also Neisseria meningitidis
Meningococcal diseases, 483
Metallo-β-lactamases, 20
Methicillin-resistant S. aureus (MRSA), 206–207
AMR in Latin America and Caribbean, 334–335
community-associated MRSA (CA-MRSA), 335
healthcare-associated MRSA, 334–335
nosocomial MRSA, 334–335
community-acquired (CAMRSA), 319, 335
hospital infections by AMR organisms in developing countries, 348
impact on AMR development, 408–409
nosocomial infections in Asia, 322–323
Methicillin-sensitive S. aureus (MSSA), 348
Microscopic observation drug susceptibility (MODS) assay, 128, 129
Middle East resistance in Middle Eastern commensals, 271
VRE in, 239–240
See also Africa; Asia; Latin America
Mold infections invasive, 148–149

See also Fungal infections
Moraxella catarrhalis, 317
Multidrug-resistant (MDR), 24–25
enteric pathogens, 177–178
Campylobacter spp., 190
E. Coli, 178–181
Helicobacter species, 190–191
K. pneumoniae, 181–182
non-typhoidal Salmonella (NTS) infections, 182–185
S. enterica Serovar Typhi, 185–186
Shigella infections, 188–190
V. cholerae, 186–188
Salmonella spp., 251, 304–305
TB, see Multidrug-resistant TB (MDR-TB)
Multidrug-resistant TB (MDR-TB), 62, 121
treating, 132–133
See also Extensively drug-resistant TB (XDR-TB)
Multi-locus sequence typing (MLST), 274
Mycobacteria growth indicator tube (MGIT), 128
Mycobacterium tuberculosis (MTB), see Tuberculosis (TB)

N
Nalidixic acid, 212
Natural resistance, see Intrinsic resistance
Neisseria gonorrhoeae
  antimicrobial use and resistance in Africa for, 305
  bacterial-resistant infections, 215–217, 260
  community-acquired STD in Asia, 319
Neisseria meningitidis, 261–262
Neonatal infections, 352–354
Newspapers
  AMR mass media analysis
    in India, 531–532
    in Latin America, 527
  See also Internet; Television
Nonfermentative gram-negative bacilli (NFB), 256–257
Non-pathogenic commensals, 268
Non-typhoid Salmonella (NTS) infections diarrheal diseases and bacteremia, 318
  multidrug-resistant, 182–184
Norfloxacin, 210
Nosocomial infections
  gram-negative pathogens
    A. baumannii, 322
    ESBLs-producing Enterobacteriaceae, 320–321
    P. aeruginosa, 321
  gram-positive pathogens
    MRSA and VISA, 322–323
    VRE, 323
    in Asia, 320–323
    MRSA, 334–335
  See also Community-acquired infections
Nucleotide reverse transcriptase inhibitors (NRTIs), 66
  HIV and, 76
  primary resistance in Latin America, 88

O
Ofloxacin, 210
Ornithine decarboxylase (ODC), 165
Oxacillinases (OXA), 259

P
Pacific region, VRE in, 233–234
Parasite, 102
Pathogenic commensals, 268
  See also Commensal bacteria
PCR methods, 275–276
Pefloxacin, 210
Penicillin
  AMR in Latin America and Caribbean, 332–333
binding protein (PBP), 19
  for N. gonorrhoeae infections, 216
  for S. aureus infections, 206
  for S. pneumoniae infections, 202–205
  impact on AMR development, 407
Penicillinas, 20
Penicillium notatum, 16
Pentamidine, 165–166
Pertussis vaccines, 480
Pharmaceutical management, see under Health systems
Pharmaceutical representative, 513–514
Pharmacies, 285–286, 288
  pharmacy education, 409
  See also Antimicrobial use
Phenotypic methods
  colorimetric methods, 129
  microscopic observation drug susceptibility (MODS) assay, 128–129
  mycobacterial growth indicator tube (MGIT), 128
Physicians, 286
  See also Antimicrobial use
Piperaquine, 97, 99
Plasmodium spp.
  P. falciparum, 61, 95, 98–99, 104–107
  P. ovale, 99
  P. vivax, 98–99
  See also Malaria
Pneumococcal infections, 201–206
  AMR in Latin America and Caribbean, 332–333
  vaccines for, 483
  See also Streptococcus pneumoniae
Pneumocystis infections, 138
  pneumocystis pneumonia (PCP), 147–148
  See also Fungal infections
Pneumonia, 201–206
  fluoroquinolones and, 206
  macrolides for, 205
  See also Klebsiella pneumoniae; Streptococcus pneumoniae
Polio vaccines, 479
Polyene, 139, 141–142
Posaconazole, 139, 141
Poverty
  AMR and
    antimicrobial quality assurance challenges, 31–32
    appropriate care and antimicrobials, access to, 30–31
resistance containment, 32–33
susceptibility to infection, 29–30
See also Antimicrobial resistance (AMR)

Prescription
antimicrobial agents, 406, 407
by qualified prescribers
bad outcomes fear, 290–291
knowledge of correct prescribing, 288
laboratory services availability, 292
peer norms and local medical cultures, 291
perceived patient demand, 291
pharmaceutical promotion pressure aspects, 292–293
unstable antimicrobial supply, 292
prescribers, 295–296
See also Dispensing

Primaquine, 97, 99
Proguanil, 97

Proportion method
critical concentrations of drugs, 127
critical proportion of resistant mutants, 126–127

Pseudomonas spp.
hospital infections by AMR organisms in developing countries, 349
P. aeruginosa
AMR in Latin America and Caribbean, 341–342
bacterial resistant infections, 256–259
nosocomial infections in Asia, 321
Pulsed field gel electrophoresis (PFGE), 275

Pyrazinamide, 125, 132
Pyrimethamine, see sulfadoxine–pyrimethamine (SP)

Q
Quinine, 97
antimalarial resistance mechanism, 105
as molecular marker of antimalarial resistance, 107

Quinolone
antimicrobial agents introduction in developing countries after, 67–68
for C. jejuni infections, 215
for Enterobacteriaceae infections, 254, 256
for N. gonorrhoeae infections, 216–217
for Salmonella infections and, 208, 251–252
for Shigella infections, 211

for V. cholerae infections, 212
resistance, 22–23
quinolone resistance-determining region (QRDR), 251–252
quinolone-resistant N. gonorrhoeae (QRNG), 216

R
Radio and television, 525–526
See also Internet
Real-time PCR, 131
Regulation, 8–9
antimicrobial agents, 404–405
regulatory issues related with antimicrobial agents introduction in developing countries, 64–65
See also Antimicrobial use
Representative, pharmaceutical, 514
Resistance ratio (RR) method, 128
Resource-limited countries (RLCs), see Developing countries
Respiratory tract infections, see under Community-acquired infections
Rhodesian sleeping sickness, 159, 161
Rifampin, 124, 132
Rifamycins, 124
Russia, primary HIV resistance in, 88

S
Salmonella spp.
AMR surveillance data for, 472
bacterial resistant infections, 249–253
extended-spectrum β-lactamases (ESBLs) in, 252
in Africa, 304, 305
multidrug-resistant (MDR), 251
non-typhoidal Salmonella (NTS) infections, 182–185, 318
quinolone resistance-determining region (QRDR) and, 251, 252
S. Paratyphi, 207–208, 317–318
S. Typhi, 207–209
multidrug-resistant, 185–186
resistance in Africa, 304
Self-medication aspect of antimicrobial use, 284–285
SENTRY program
for Enterobacteriaceae infections, 253–256
Pseudomonas and Acinetobacter infections, 257–259
SENTRY program (cont.)

Salmonella infections and, 250
See also Surveillance

Sequencing, see DNA sequencing

Sexually transmitted diseases (STD), see HIV; Neisseria gonorrhoeae

Shigella spp.
AMR surveillance data for, 472
bacterial-resistant infections, 209–211, 252–253
multidrug-resistant infections, 188–190
S. boydii, 209
S. dysenteriae, 188–189, 209–210, 252
S. flexneri, 209, 211, 252
S. sonnei, 209, 252

Sleeping sickness
Gambian, 159
Rhodesian, 159
See also Human African trypanosomiasis (HAT)

Solid-phase hybridization techniques, 130

Spectinomycin, 216

Staphylococcus spp., 16
coagulase-negative (CONS), 349
S. aureus
AMR surveillance data for, 472
bacterial-resistant infections, 206–207
community-acquired methicillin-resistant (CAMRSA), 319
methicillin-resistant (MRSA), 206–207, 322–323, 334
nosocomial infections in Asia, 322–323
vancomycin-intermediate (VISA), 322–323

Sterile insect technique (SIT), 160

Streptococcus pneumoniae
AMR surveillance data for, 472
bacterial-resistant infections, 201–206
respiratory tract infections, 315–317
TMP–SMZ resistance and, 204–205

Streptococcus pyogenes
macrolide-resistant, 317
See also Community-acquired infections

Streptogramin, see Macrolide, lincosamide, and streptogramin (MLS)

Streptomycin (SM), 121, 212
Substandard anti-infectives, see Counterfeit drugs

Sulfadoxine–pyrimethamine (SP), 96, 112
antimalarial resistance mechanism, 104–105

as molecular marker of antimalarial resistance, 106–107
drug-resistant malaria and, 97, 100
switching therapy economics example, 374

Sulfamethoxazole, 142–143
See also Trimethoprim–sulphamethoxazole (TMP–SMZ)

Sulfonamides, 24

Suramin, 165

Surveillance
antimicrobial agents intervention and, 410
AST and, 464
at national level
Africa, 468–469
Asia, 467–468
Northern Africa, 469
available data (Asia), 467–468
blood cultures for, 465
capability improvement needs, 465
definitions, 465
funding impact, 466–467
in Latin America and Caribbean, 332
manpower and human resources, 467
microbiological gap aspects, 464
need of, 463
organising problems, 466
planning and development, 466
resistance data on key pathogens
E. coli, 471–472
enteric pathogens, 470–471
Enterobacteriaceae, 471–472
S. aureus, 469–470
S. pneumoniae, 470
through commensal bacteria, 218
WHONET and, 465–466

Switching therapy, 372

SXT constins, 212

Tanzania health system (AMR access case study)
lessons learned, 398
problem, 394–395
results, 395–398
strategy for change, 395
See also Health systems

Television
AMR mass media analysis in
India, 533
in Latin America, 525–526
See also Internet

Tetanus vaccines, 481
Tetracycline for *N. gonorrhoeae* infections, 216
for *Shigella* infections, 2210
for *V. cholerae* infections, 212
impact on AMR development, 407
resistance, 20
efflux of antibiotics, 21
modification of antibiotic, 21
ribosome protection, 21
Thin-layer chromatography (TLC), 430
Trimethoprim, 24
Trimethoprim–sulphamethoxazole (TMP–SMZ) for *S. pneumoniae* infections, 204–205
for *Shigella* infections and, 210
for *V. cholerae* infections, 212
Trypanocidal, 161
*Trypanosoma b. gambiense*, 158
*Trypanosoma b. rhodesiense*, 158–159
*Trypanosoma congolense*, 158
*Trypanosoma evansi*, 158
*Trypanosoma vivax*, 158
Trypanosomiasis, see African trypanosomiasis
Tuberculosis (TB)
drug resistance acquired, 119–120
controlling, 133
development, 121, 124
in Asia, 323
in developing countries, 117–133
MDR-TB, 121
mono resistance, 120
primary, 119
surveillance aspects, 133
treatment, 132–133
XDR-TB, 119
drug susceptibility testing (DST), 125
absolute concentration method, 128
colorimetric methods, 129
conventional susceptibility methods, 126–128
direct detection of drug resistance, 131
DNA sequencing, 130
genotypic methods, 130–131
implementation issues in, 131
MGIT, 128
MODS assay, 128–129
phenotypic methods, 128–129
proportion method, 126–127
real-time PCR, 131
resistance ratio method, 128
solid-phase hybridization techniques, 130
epidemiology, 117–119
MDR-TB, 118–119
XDR-TB, 119
extensively drug-resistant (XDR-TB), 62
HIV-associated, 118
mechanism of resistance to anti-TB drugs, 124–126
multidrug-resistant (MDR-TB), 62
terminology
acquired drug resistance, 119–120
MDR-TB, 121
mono resistance, 120
new case of TB, 119
previously treated TB patient, 119
primary drug resistance, 119
XDR-TB, 119
vaccine, 481
Typhoid
*Salmonella* enterica infections, 207–209
*S. Paratyphi*, 207–208, 317–318
*S. Typhi*, 207–209, 185–186, 304
surveillance, 471–472

U
Upper respiratory tract infections (URTIs), 500
UV-Vis detection, 428

V
Vaccines
against infectious disease
bacterial infections, 480–481
viral infections, 479–480
cost-effectiveness, 479–480, 486
diphtheria, 480
EPI and, 482, 487
for AMR containment, 477–478
for future, 483–485
HCV, 479
Hib, 481
measles, 479
meningococcal disease, 483
newer vaccines, 483
pertussis, 480
pneumococcal diseases, 483
polio, 479
TB, 481
tetanus, 481
why choose vaccines?, 485
Vancomycin-intermediate *S. aureus* (VISA)
AMR in Latin America and Caribbean, 335
nosocomial infections in Asia, 320–321

Vancomycin-resistant enterococci (VRE)
AMR in Latin America and Caribbean, 336
hospital infections by AMR organisms in developing countries, 347
impact on AMR development, 408
in Central Asia and Europe, 234–236
in East Asia and Pacific, 233–234
in Latin America and Caribbean, 236–239
in Middle East and North Africa, 239–240
in South Africa, 240
nosocomial infections in Asia, 322
Variant antigen types (VATs), 160
Vector, 104
*See also* Host; Malaria

*Vibrio cholerae*
AMR surveillance data for, 472
bacterial-resistant infections, 211–213
in Africa, 303, 304
multidrug-resistant, 186–188
O1 serogroup, 212–213
O139 serogroup, 211–213

*Vibrio parahaemolyticus*, 188
Viral infections, vaccines against, 479–480
Voriconazole, 139, 141, 145
Vulvovaginal candidiasis, 146

W
WHO
Global Salm-Surv project, 249–250
Global Strategy for Containment of Antimicrobial Resistance, 464
WHONET, 465–466
*See also* Surveillance
Wide-spectrum antibiotics, 6

X
XDR-TB, *see* Extensively drug-resistant TB
(XDR-TB)

Z
Zidovudine (ZDV), 76
Zoonosis, 158–159
*See also* Human African trypanosomiasis (HAT)
Zygomycetes, 149